Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Eduardo Montoya-Diaz

Former Member


Development a novel P. vivax vaccine using virus like particle platforms and rodent challenge models

To date, vaccination remains the most effective way for control and prevention of infectious diseases and this approach has yet to demonstrate its potential for any parasitic disease, including malaria. Malaria caused by Plasmodium vivax seriously challenges human health, attacking 100 to 400 million people each year among the 2.5 billion living at endemic risk.

P. vivax vaccines have rarely reached Phase I or II trials, the leading and most effective P. falciparum malaria vaccine RTS,S has been tested in large-scale phase III trials. This vaccine consists of Virus-like particles (VLPs). VLPs are formed by structural viral proteins, which have an inherent property for self-assembly and mimic the morphology of a pathogen. In contrast to live viruses, VLPs are non-infective and non-replicating since they are essentially devoid of infectious genetic material. VLPs display antigenic epitopes in the correct conformation and in a highly repetitive manner, leading to cross linking of B cell immunoglobulin receptors and B cell activation

The objective of my project is to set up a model of VLP vaccination against P. vivax malaria, using recombinant Virus Like Particle (rVLP) with the DNA sequence of circumsporozoite protein (CSP) from P. vivax and a small envelop protein from the hepatitis B virus (HBsAg-S) in order to improve the antigenicity of  CSP for induce an effective persistent immune response.

Key publications

Rhea J. Longley, Arturo Reyes-Sandoval, Eduardo Montoya-Diaz, Susanna Dunachie, Chalermpon Kumpitak, Wang Nguitragool, Ivo Mueller, Jetsumon Sattabongkot. “Acquisition and longevity of antibodies to Plasmodium vivax pre-erythrocytic antigens in Western Thailand.” In Press, 2015.

Yadira Ledesma-Soto, Francisco Blanco-Favela, Ezequiel M Fuentes- Panana, Emiliano Tesoro-Cruz, Rafael Hernandez-Gonzalez, Lourdes Arriaga-Pizano, Maria V Legorreta-Haquet, Eduardo Montoya-Diaz, Luis Chavez-Sanchez, Maria E Castro-Mussot and Adriana K Chavez-Rueda. “Increased levels of prolactin receptor expression correlate with the early onset of lupus symptoms and increased numbers of transitional-1 B cells after prolactin treatment.” BMC Immunol. 2012;13(11).

Montoya-Díaz E, Cervera-Castillo H, Chávez-Sánchez L, Legorreta-Haquet MV, Sánchez-González L, Chávez-Rueda K, Blanco-Favela F. “Prolactin promoter polymorphism (-1149 G/T) is associated with ANTI-DNA antibodies in Mexican patients with systemic lupus erythematosus.” Immunol Invest. 2011; 40(6):614-26.